Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) target price raised to $6.00, reported today by FBR & Co
- Updated: September 15, 2016
Boasting a price of $1.54, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded 2.67% higher on the day. The last close is down 9.81% from the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time. The company has logged a 50-day moving average of $1.63 and 200-day average of $1.71. Trading volume was was down over the average, with 1,339,215 shares of ARNA changing hands under the typical 1,446,750 shares.
FBR & Co bumped the target stock price of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to $6, reporting a possible upside of 2.90%,
On 10/28/2015, WallachBeth reported on Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) dropped the target price from $6.00 to $4.00 that indicated a possible upside of 0.00%.
Arena Pharmaceuticals, Inc. has a 52 week low of $1.30 and a one-year high of $2.96 and has a market cap of $0.0.
General Information About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, and temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.